ScientificWorldJournal. 2026;2026(1):e1824689. doi: 10.1155/tswj/1824689.
ABSTRACT
BACKGROUND: Myofascial trigger points (MTrPs) in the upper trapezius are a common source of chronic neck and shoulder pain. Although deep friction massage combined with ischemic compression (DMIS) and acupuncture (AC) using the reducing (xie) technique are widely utilized, comparative evidence remains limited.
OBJECTIVE: This study is aimed at comparing the therapeutic effects of DMIS versus AC on pain intensity, 24-hour pain frequency, pressure pain threshold (PPT), muscle tension, anxiety, and cervical flexion range of motion (CFROM) in individuals with upper trapezius MTrPs.
METHODS: In this assessor-blinded randomized controlled trial, 82 participants with active MTrPs were randomly assigned to the DMIS or AC group. Both interventions were administered three times weekly for 3 weeks. Pain intensity and perceived muscle tension evaluated via visual analog scale (VAS), 24-hour pain frequency, PPT measured via pressure algometry, anxiety evaluated using the State-Trait Anxiety Inventory (STAI), and CFROM measured via goniometry were evaluated at baseline, postintervention, and 1-month follow-up.
RESULTS: Both groups demonstrated significant improvements in pain intensity, 24-hour pain frequency, perceived muscle tension, anxiety, and CFROM following the intervention (p < 0.05). At the 1-month follow-up, these improvements were generally maintained, except for anxiety levels. The DMIS group showed significant increases in PPT at both postintervention and the 1-month follow-up (p < 0.05), whereas no significant change in PPT was observed in the AC group. Furthermore, PPT values were significantly higher in the DMIS group compared with the AC group at all assessment points (p < 0.05). No significant between-group differences were found for the other outcomes at any time point (p > 0.05).
CONCLUSION: Both DMIS and AC effectively alleviate pain, muscle tension, anxiety, and mobility restrictions in individuals with upper trapezius MTrPs. However, DMIS provides superior, sustained benefits in modulating pain sensitivity by significantly elevating the PPT.
TRIAL REGISTRATION: Thai Clinical Trials Registry:TCTR20210127003.
PMID:43059203 | DOI:10.1155/tswj/1824689
